Sutro Biopharma, Inc. (STRO) Tops Q3 EPS by 14c

Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q3 EPS of ($0.59), $0.14 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $15.29 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Keurig Dr Pepper coffee chief to depart ahead of planned split
• Jinxin Technology plans 1-for-25 reverse ADS split